How to improve on the outcome in RAS mutant tumors

How to improve on the outcome in RAS mutant tumors

Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTCПодробнее

Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

AC21 - Ardaman Shergill: MAPK Pathway Targeting in CholangiocarcinomaПодробнее

AC21 - Ardaman Shergill: MAPK Pathway Targeting in Cholangiocarcinoma

Improving outcomes in KRAS-mutant pancreatic cancerПодробнее

Improving outcomes in KRAS-mutant pancreatic cancer

Genomic and Molecular Markers in Glioma : Where Are We Now?Подробнее

Genomic and Molecular Markers in Glioma : Where Are We Now?

From MDS to AML: What Every Patient Needs to Know 11/28/17Подробнее

From MDS to AML: What Every Patient Needs to Know 11/28/17

Drugging the Undruggable Cancer TargetsПодробнее

Drugging the Undruggable Cancer Targets

Targeting the MAPK Pathway in GI MalignanciesПодробнее

Targeting the MAPK Pathway in GI Malignancies